Anti-glypican 3 (GPC3) antibody that boosts ADCC/CDC to unlock next-gen liver cancer immunotherapy.
The antibody binds a defined region of glypican-3 (GPC3) on tumor cells, triggering immune killing via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Its technical edge is that it reports higher ADCC and CDC activity than conventional anti-GPC3 antibodies, improving the “kill” signal delivered to immune effector cells. Previously, therapeutic and diagnostic development using this specific anti-GPC3 binding/engineered antibody required patent licensing from the assignee.
Develop GPC3-targeted antibody-based diagnostics or next-gen ADC-agnostic immunotherapies for hepatocellular carcinoma without paying royalties.
An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.
Post a problem you're solving with this technology and connect with founders, investors, and researchers.